ClinicalTrials.gg
Active, not recruitingNCT04480853SPRINGUpdated Nov 9, 2026

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

A Phase 4 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 3 sites in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionMultiple Sclerosis, Relapsing-RemittingRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Relapsing-Remitting
Why
  1. The study's title name Multiple Sclerosis, Relapsing-Remitting, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Updated Nov 9, 2026Now Active, not recruitingStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
17th of 19
14 · median 142
Started
2020
the only one that year
Phase 4
14 of 19
none open now
Registered
19th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 17th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 4, and was the 19th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.

Read the detailed description

This is a 12-month, prospective, interventional, multi-center study to monitor safety in adult patients with relapsing-remitting multiple sclerosis (RRMS) in Taiwan who based on local practice are newly starting fingolimod at the time of study entry.

Thirty-four patients will be included in this study in line with the study inclusion and exclusion criteria. After entering this study, the participants will continue to be treated for MS based on local practice. The patient will be taking fingolimod 0.5mg per day. Protocol-mandated procedures and visits for safety data collection will be conducted in addition to the required examinations according to the clinical practice.

If a patient experienced an interruption of fingolimod treatment that requires a re-evaluation of FDO, the patient will be discontinued from the study. If the treatment interruption does not require a FDO when re-starting fingolimod, the patient can continue to participate in this study.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Fingolimod
  • Multiple sclerosis
  • Relapsing-remitting multiple sclerosis
  • Relapsing-remitting
  • Post-authorization study
  • Adult
  • MS
04

In context

Multiple Sclerosis, Relapsing-Remitting Reclassified

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 14 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients with relapsing-remitting multiple sclerosis that are fingolimod treatment naive at the time of study entry and are newly starting fingolimod based on physician judgement and according to Taiwan's fingolimod package insert (version TWI-090420)

Exclusion criteria

Exclusion Criteria:

  • Patients with the diagnosis of neuromyelitis optica.
  • Patients who are being treated with any drug at the time of study entry.
  • In the last 6 months experienced myocardial infarction, unstable angina, stroke, , decompensated heart failure requiring hospitalization or Class III/IV heart failure
  • A history or presence of Mobitz Type II second-degree or third-degree atrioventricular block or sick sinus syndrome, unless patient has a functioning pacemaker
  • A baseline ≥ 500 msec
  • Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
  • Patient with known immune deficiency, increased risk of opportunistic infection, severe active infection or chronic active infection.
  • Patients with severe active , except for basal cell epithelioma
  • Patients with severe hepatic insufficiency
  • Pregnant or nursing (lactating) women or women of unless on
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Open label Fingolimod 0.5 mg capsule taken once daily, oral.

    Drug: Fingolimod

Interventions

  • Fingolimod 0.5 mg QD, oral

    Also known as: FTY720

07

What researchers measure

Primary outcomes

  1. Number of Adverse Events of Special Interest(AESI)

    The adverse events of special interest (AESI) include bradycardia and Grade 2 or higher AV block during First Dose Observation.

    Time frame: First Dose Observation on the first day of taking findolimod

  2. Number of Adverse Events of Special Interest (AESI)

    The adverse events of special interest (AESI) include macular edema, abnormal liver function(ALT, AST or GGT \> 5x upper normal limit), and severe lymphocytopenia(lymphocyte \< 200 cells/μL).

    Time frame: Baseline up to 12 months

Secondary outcomes

  1. Annualized relapse reate (ARR)

    The ARR will be calculated as total number of relapses experienced divided by total number of days of follow-up, and the ratio multiplied by 365. For patients withdraw from the study or switch to an alternative MS therapy prior to 12 month, the total number of days in study is defined as the number of days from baseline to the last date in study.

    Time frame: Baseline up to 12 months

  2. Change from baseline of Pulse (beats/min)

    Pulse (beats/min - bpm) data will be summarized as descriptive statistics for change from baseline value (both for the period 6-hours post first dose and for further visit assessments). The frequency and percentage of notable vital sign abnormalities will be summarized. Notable criteria for pulse is \> 120bpm or Increase of ≥15 bpm from baseline Or \< 50bpm or Decrease of ≥15 bpm from baseline

    Time frame: Baseline up to 12 months

  3. Change from baseline of blood pressure (mmHg)

    Blood pressure(BP)(mmHg) data will be summarized as descriptive statistics for change from baseline value (both for the period 6-hours post first dose and for further visit assessments). The frequency and percentage of notable vital sign abnormalities will be summarized. Notable criteria for systolic BP is ≥160 mm Hg or Increase of ≥20 mm Hg from baseline Or ≤ 90 mm Hg or Decrease of ≥ 20 mm Hg from baseline. Notable criteria for diastolic BP is ≥ 100 mmHg or Increase of ≥ 15 mm Hg from baseline Or ≤ 50 mmHg or Decrease of ≥ 15 mm Hg from baseline.

    Time frame: Baseline up to 12 months

08

Study locations

3 sites
  • Novartis Investigative Site
    Kaohsiung City, 833, Taiwan
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
09

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Oct 2026, 72 months.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 72 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Oct 2026, on Nov 2, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 21, 2020
StartActual
Oct 12, 2020
Primary completionActual
Oct 15, 2026was Sep 2027
CompletionEst.
Nov 15, 2026was Sep 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 2, 2026
Sites
3 sites removed
Show 3 removed
  • Novartis Investigative Site · Tainan, Taiwan
  • Novartis Investigative Site · Taipei, Taiwan
  • Novartis Investigative Site · Taoyuan, Taiwan
Nov 2, 2026
Primary completion
Sep 30, 2027→Oct 15, 2026 (actual)
Nov 2, 2026
Study completion
Sep 30, 2027→Nov 15, 2026
Nov 9, 2026
Enrollment
30 (estimated)→14 (actual)
Nov 2, 2026
Show all 2 updates
  1. Nov 9, 2026
    Study completion Sep 30, 2027→Nov 15, 2026
    + 2 other changes: verification date and site details
  2. Nov 2, 2026
    Recruiting→Active, not recruiting
    3 sites removed
    Show 3 removed
    • Novartis Investigative Site · Tainan, Taiwan
    • Novartis Investigative Site · Taipei, Taiwan
    • Novartis Investigative Site · Taoyuan, Taiwan
    Primary completion Sep 30, 2027→Oct 15, 2026 (now actual)
    Enrollment 30 (estimated)→14 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04480853
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Oct 12, 2020
Primary completion
Oct 15, 2026
Completion
Nov 15, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion